apparently fda approve anything antidepressant despite patients indicating perceive abilify work antidepressant fda approved likely leading tens thousands americans able enjoy taste akathisia getting psychological benefits placebo good work fda shift antipsychotics antidepressants documented many places ironically depressing fda anything goes attitude regarding antidepressants apparently extends mediocre medical devices paper biological psychiatry presented results large trial comparing tms sham tms article concluded treatment fantastic option depression well close anyway actually wrote transcranial magnetic stimulation effective treating major depression minimal side effects reported offers clinicians novel alternative treatment disorder poor depressed souls get line sweet magnetic stimulation maybe like look evidence primary measure outcome montgomery asberg depression rating scale results quite statistically significant sponsor tried convince fda neurological devices panel secondary measures showed super impressive results problem fda review panel thought things seen entirety panel consensus efficacy established stated device effectiveness small borderline marginal questionable clinical significance study endpoint p value per se considered fatal flaw study analysis panel believe clinical significance demonstrated results general panel believed analyses secondary effectiveness endpoints contribute significant information help establish effectiveness device panel agreed unblinding greater active group considering magnitude effect size may influenced study results people receiving tms reported pain application site compared sham tms group quick way make study unblind people experiencing pain could logically surmise receiving tms panel stated many non random dropouts reliably interpret results panel consensus week data limited value provide supportive data establishing effectiveness week patients show adequate improvement given option quit double blind study half patients departed study week one doozy quote follows letter editor biological psychiatry tms taken task authors note patient outcome measures collected trial omitted article secondary end points authors included paper statistically significant secondary end points included statistically significant thus published end points three times likely statistically significant unpublished ones tms denied fda approval january october fda change heart approving device i quite sure changed mind fda following disclaimer device website bit funny neurostar tms therapy studied patients received prior antidepressant treatment effectiveness also established patients failed receive benefit two prior antidepressant medications minimal effective dose duration current episode demonstrated weak efficacy people failed one zero one antidepressant trial impressive eh summarize sponsor affiliated academics wrote paper major psychiatry journal positive outcomes three times likely reported negative outcomes efficacy data unimpressive according fda panel panels known particularly choosy efficacy data seemed tms dead water resurrected form surprising fda approval resurrected grave make great halloween post offending study reardon solvason janicak p sampson isenberg k nahas z mcdonald avery fitzgerald p loo efficacy safety transcranial magnetic stimulation acute treatment major depression multisite randomized controlled trial biological psychiatry doi biopsych letter editor yu lurie p transcranial magnetic stimulation proven effective biological psychiatry doi biopsych